Background: Acute kidney injury (AKI) is a serious complication of COVID-19. Methods: Records of hospitalized adult patients with confirmed SARS-CoV-2 infection from 1 March to 31 May 2020 were retrospectively reviewed. Results: Of 283 patients, AKI occurred in 40.6%. From multivariate analyses, the risk factors of AKI in COVID-19 can be divided into: (1) demographics/co-morbidities (male, increasing age, diabetes, chronic kidney disease); (2) other organ involvements (transaminitis, elevated troponin I, ST segment/T wave change on electrocardiography); (3) elevated biomarkers (ferritin, lactate dehydrogenase); (4) possible bacterial co-infection (leukocytosis, elevated procalcitonin); (5) need for advanced oxygen delivery (non-invasive positive pressure ventilation, mechanical ventilation); and (6) other critical features (ICU admission, need for vasopressors, acute respiratory distress syndrome). Most AKIs were due to pre-renal (70.4%) and intrinsic (34.8%) causes. Renal replacement therapy was more common in intrinsic AKI. Both pre-renal (HR 3.2; 95% CI 1.7-5.9) and intrinsic AKI (HR 7.7; 95% CI 3.6-16.3) were associated with higher mortality. Male, stage 3 AKI, higher baseline and peak serum creatinine and blood urea nitrogen were prevalent in intrinsic AKI. Urine analysis and the fractional excretion of sodium and urea were not helpful in distinguishing intrinsic AKI from other causes. Conclusions: AKI is very common in COVID-19 and is associated with higher mortality. Characterization of AKI is warranted due to its diverse nature and clinical outcome.
Background: Acute kidney injury (AKI) is a serious complication of COVID-19. Methods: Records of hospitalized adult patients with confirmed SARS-CoV-2 infection from 1 March to 31 May 2020 were retrospectively reviewed. Results: Of 283 patients, AKI occurred in 40.6%. From multivariate analyses, the risk factors of AKI in COVID-19 can be divided into: (1) demographics/co-morbidities (male, increasing age, diabetes, chronic kidney disease); (2) other organ involvements (transaminitis, elevated troponin I, ST segment/T wave change on electrocardiography); (3) elevated biomarkers (ferritin, lactate dehydrogenase); (4) possible bacterial co-infection (leukocytosis, elevated procalcitonin); (5) need for advanced oxygen delivery (non-invasive positive pressure ventilation, mechanical ventilation); and (6) other critical features (ICU admission, need for vasopressors, acute respiratory distress syndrome). Most AKIs were due to pre-renal (70.4%) and intrinsic (34.8%) causes. Renal replacement therapy was more common in intrinsic AKI. Both pre-renal (HR 3.2; 95% CI 1.7-5.9) and intrinsic AKI (HR 7.7; 95% CI 3.6-16.3) were associated with higher mortality. Male, stage 3 AKI, higher baseline and peak serum creatinine and blood ureanitrogen were prevalent in intrinsic AKI. Urine analysis and the fractional excretion of sodium and urea were not helpful in distinguishing intrinsic AKI from other causes. Conclusions: AKI is very common in COVID-19 and is associated with higher mortality. Characterization of AKI is warranted due to its diverse nature and clinical outcome.
Authors: Safiya Richardson; Jamie S Hirsch; Mangala Narasimhan; James M Crawford; Thomas McGinn; Karina W Davidson; Douglas P Barnaby; Lance B Becker; John D Chelico; Stuart L Cohen; Jennifer Cookingham; Kevin Coppa; Michael A Diefenbach; Andrew J Dominello; Joan Duer-Hefele; Louise Falzon; Jordan Gitlin; Negin Hajizadeh; Tiffany G Harvin; David A Hirschwerk; Eun Ji Kim; Zachary M Kozel; Lyndonna M Marrast; Jazmin N Mogavero; Gabrielle A Osorio; Michael Qiu; Theodoros P Zanos Journal: JAMA Date: 2020-05-26 Impact factor: 56.272
Authors: Pouneh Golmai; Christopher P Larsen; Maria V DeVita; Samuel J Wahl; Astrid Weins; Helmut G Rennke; Vanesa Bijol; Jordan L Rosenstock Journal: J Am Soc Nephrol Date: 2020-07-16 Impact factor: 10.121
Authors: Raúl Lombardi; Nicolás Nin; Oscar Peñuelas; Alejandro Ferreiro; Fernando Rios; Maria Carmen Marin; Konstantinos Raymondos; Jose A Lorente; Younsuck Koh; Javier Hurtado; Marco Gonzalez; Fekri Abroug; Manuel Jibaja; Yaseen Arabi; Rui Moreno; Dimitros Matamis; Antonio Anzueto; Andres Esteban Journal: Shock Date: 2017-10 Impact factor: 3.454
Authors: V Arroyo; P Ginès; A L Gerbes; F J Dudley; P Gentilini; G Laffi; T B Reynolds; H Ring-Larsen; J Schölmerich Journal: Hepatology Date: 1996-01 Impact factor: 17.425
Authors: Andrew S Levey; Lesley A Stevens; Christopher H Schmid; Yaping Lucy Zhang; Alejandro F Castro; Harold I Feldman; John W Kusek; Paul Eggers; Frederick Van Lente; Tom Greene; Josef Coresh Journal: Ann Intern Med Date: 2009-05-05 Impact factor: 25.391
Authors: Bak Leong Goh; Malini Shanmuganathan; Kalaiarasu Peariasamy; Nor Arisah Misnan; Suresh Kumar Chidambaram; Eddie Fook Sem Wong; Mohan Dass Pathmanathan; Kim Liong Ang; Hin Seng Wong; Lena Lay Ling Yeap Journal: Nephrology (Carlton) Date: 2022-05-07 Impact factor: 2.358
Authors: Laila A Damiati; Sami Bahlas; Ahmed Aljohaney; Yasser Bawazir; Mohammad Mustafa; Iuliana Denetiu; Peter N Pushparaj Journal: J Infect Public Health Date: 2022-01-06 Impact factor: 3.718
Authors: Tyler Pitre; Angela Hong Tian Dong; Aaron Jones; Jessica Kapralik; Sonya Cui; Jasmine Mah; Wryan Helmeczi; Johnny Su; Vivek Patel; Zaka Zia; Michael Mallender; Xinxin Tang; Cooper Webb; Nivedh Patro; Mats Junek; MyLinh Duong; Terence Ho; Marla K Beauchamp; Andrew P Costa; Rebecca Kruisselbrink; Jennifer L Y Tsang; Michael Walsh Journal: Can J Kidney Health Dis Date: 2021-07-11
Authors: Tayfun Birtay; Suzan Bahadir; Ebru Kabacaoglu; Ozgur Yetiz; Mehmet Fatih Demirci; Gultekin Genctoy Journal: Ann Saudi Med Date: 2021-12-02 Impact factor: 1.707